Metronomic Capecitabine Gives Durable 10‑Year DFS Benefit in Early Triple‑Negative Breast Cancer — FOXC1 May Identify Who Benefits
Highlight
– The SYSUCC‑001 trial reports a sustained 10‑year disease‑free survival (DFS) benefit with 1 year of metronomic capecitabine versus observation in operable triple‑negative breast cancer (78.1% vs 66.6%; HR 0.61; p=0.0074).
– Distant DFS and locoregional recurrence‑free survival were similarly improved; overall survival (OS) showed a strong trend but did not reach conventional significance at 10 years (HR 0.67; p=0.058).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.